TENAX THERAPEUTICS, INC. Overview
Pro stress-test →Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company developing novel cardiopulmonary therapies, with global rights to develop and commercialize levosimendan for treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. TNX-103 targets a large, underserved PH-HFpEF market (~1.4 million US patients) with no approved therapies; pivotal Phase 3 readout expected in second half 2026.
Strategic Profile
Pro stress-test →The company completed randomization of more than 230 patients in the Phase 3 LEVEL study positioned to deliver topline data in third quarter 2026, with Piper Sandler raising its price target from $20 to $50 in June 2026, reflecting growing confidence in the company's drug development pipeline and impending clinical milestones for TNX-103. Cash position of $118.8 million is expected to fund operations through at least Q1 2028.
Competitive Landscape
Pro stress-test →TNX-103 addresses PH-HFpEF, the most prevalent pulmonary hypertension form with no approved therapies, positioning it as a first-mover advantage candidate. Potential competitors include other cardiopulmonary and pulmonary hypertension developers, though TNX-103's oral levosimendan formulation represents a novel mechanism in an underserved market.
Industry Context
TENAX THERAPEUTICS, INC. operates in Clinical-stage cardiovascular and pulmonary hypertension drug development.
Key facts
Founded: N/A · Headquarters: Chapel Hill, US · Employees: N/A · Revenue: $0M · Market cap: $284.6M